Compare Hilton Hotels Corporation Common Stock (HLT) vs Heron Therapeutics Inc (HRTX) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Hilton Hotels Corporation Common Stock vs Heron Therapeutics Inc — how do they compare? Hilton Hotels Corporation Common Stock trades at $328 (market cap $73.63B), while Heron Therapeutics Inc trades at $0.47 (market cap $91.46M). The key difference: Hilton Hotels Corporation Common Stock is far larger — about 805.1× Heron Therapeutics Inc's market cap, and Hilton Hotels Corporation Common Stock pays a 0.19% dividend while Heron Therapeutics Inc pays none. Which is the better fit depends on your goals.
| HLT | HRTX | |
|---|---|---|
Market Cap | $73.63B | $91.46M |
Sector | Consumer Cyclical | Health |
52-Week High | $350.22 | $1.96 |
52-Week Low | $256.75 | $0.39 |
Enterprise Value | $86.12B | $189.36M |
Dividend Yield | 0.19% | — |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Hilton Worldwide Holdings (HLT) trades at $323.22, up 0.59% with a bearish technical signal despite consistent earnings beats. The company shows strong fundamentals with 2025 revenue of $12.04B and net income of $1.46B, though valuation metrics appear elevated with a P/E of 49.06. Recent developments include brand expansion initiatives and upcoming Q2 2026 earnings on July 28, 2026.
Wall Street maintains a bullish outlook with 55% buy ratings and a $345.18 price target, representing 6.8% upside. Key risks include rising debt levels (debt-to-asset ratio increased to 73.88% in 2025) and technical weakness. The stock offers growth potential through Hilton's brand expansion but faces headwinds from high valuation and negative shareholder equity.
HRTX trades at $0.4804, up 2.06% today, with a bullish technical signal despite mixed earnings. The stock shows a low price-to-sales ratio of 0.51 but negative profitability, with a net income margin of -20.53% in 2026. Recent Q1 2026 earnings missed expectations, though management reaffirmed full-year guidance. Analyst consensus is strongly bullish with 94.7% buy ratings.
Outlook remains speculative given persistent losses and cash burn, but potential upside exists if operational improvements materialize. Key risks include patent litigation outcomes and reliance on revenue growth to achieve profitability. Investors should weigh high analyst optimism against fundamental challenges.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
About Hilton Hotels Corporation Common Stock
Hilton Worldwide Holdings operates 1,074,791 rooms across its 18 brands addressing the midscale through luxury segments as of Dec. 31, 2021. Hampton and Hilton are the two largest brands by total room count at 28% and 21%, respectively, as of Dec. 31, 2021. Recent brands launched over the last few years include Home2, Curio, Canopy, Tru, and Tempo. Managed and franchised represent the vast majority of adjusted EBITDA, predominantly from the Americas regions.
Read more on HLT →About Heron Therapeutics Inc
Heron Therapeutics is a commercial-stage biotechnology company focused on improving patient care. It develops best-in-class medicines for pain management and cancer care to address unmet medical needs.
Read more on HRTX →
